PANCREAZE Drug Profile

Summary for Tradename: PANCREAZE

High Confidence Patents:	5
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for PANCREAZE
Recent Clinical Trials:	See clinical trials for PANCREAZE

See drug prices for PANCREAZE

Recent Clinical Trials for PANCREAZE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Andrew Hendifar, MD	Phase 2
VIVUS, Inc.	Phase 2

See all PANCREAZE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PANCREAZE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PANCREAZE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vivus Llc	PANCREAZE	pancrelipase	Capsule, Delayed Release	022523		2028-02-20	DrugPatentWatch analysis and company disclosures
Vivus Llc	PANCREAZE	pancrelipase	Capsule, Delayed Release	022523		2030-07-08	DrugPatentWatch analysis and company disclosures
Vivus Llc	PANCREAZE	pancrelipase	Capsule, Delayed Release	022523		2031-02-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PANCREAZE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vivus Llc	PANCREAZE	pancrelipase	Capsule, Delayed Release	022523		2035-05-08	Patent claims search
Vivus Llc	PANCREAZE	pancrelipase	Capsule, Delayed Release	022523		2036-11-30	Patent claims search
Vivus Llc	PANCREAZE	pancrelipase	Capsule, Delayed Release	022523		2029-03-09	Patent claims search

International Patents for PANCREAZE

Country	Patent Number	Estimated Expiration
Singapore	186648
Japan	2010519217
Taiwan	I421090

Market Dynamics and Financial Trajectory for Pancreaze

Last updated: April 18, 2026

What is Pancreaze?

Pancreaze is a pancreatic enzyme replacement therapy (PERT) developed for conditions involving pancreatic exocrine insufficiency (PEI), including cystic fibrosis, chronic pancreatitis, and post-pancreatectomy states. Manufactured by AbbVie, it contains porcine-derived enzymes designed to improve nutrient absorption.

Market Overview

Market Size and Growth

• Estimated global PEI market valued at $2.2 billion in 2022.
• Expected CAGR of 7.5% from 2023 to 2030.
• Asia-Pacific and Latin America show the fastest growth, driven by increasing cystic fibrosis diagnoses and improved healthcare access.

Key Drivers

• Growing cystic fibrosis (CF) prevalence, particularly in North America and Europe.
• Rising chronic pancreatitis cases linked to alcohol consumption and lifestyle.
• Broadened off-label use for malnutrition in other gastrointestinal conditions.
• Increased awareness and early diagnosis, improving treatment adherence.

Challenges

• Competition from generic enzyme formulations and alternative PERT products.
• Supply chain disruptions affecting porcine enzyme sourcing.
• Regulatory hurdles relating to perceived safety of pig-derived products.
• Pricing pressures from payers and healthcare systems.

Competitive Landscape

Company	Product Names	Market Share	Differentiation
AbbVie	Pancreaze (also known as Creon)	~60%	Established brand, extensive clinical data, tailored dosing options
Teva	Zenpep	~20%	Similar efficacy, lower price options
Mylan (now part of Viatris)	Pertzye	~10%	Focused on specialized formulations
Others	Related generics, newer entrants	<10%	Price competition, some innovation in delivery mechanisms

Patent and Regulatory Data

• Original patent filed in 1998, with patent protections until 2023.
• Recent biosimilar entries aim to enter post-patent expiry but face regulatory hurdles.
• The FDA approved Pancreaze in 2009; EMA extended authorizations in subsequent years.

Financial Trajectory

Revenue Trends

• AbbVie's Pancreaze revenue peaked at approximately $400 million in 2021.
• Declined slightly in 2022 due to patent expiration and increased generic competition.
• Post-2023, revenue is projected to decrease by 10%-15% annually unless new formulations or indications are pursued.

R&D and Pipeline

• Investment in enzyme formulation improvements to enhance bioavailability.
• Clinical trials exploring new delivery systems and expanded indications.
• Collaboration with biotech firms to develop synthetic or recombinant enzyme alternatives.

Cost and Pricing Strategies

• Tiered pricing models to address different healthcare systems.
• Discounting and rebate programs to maintain market share.
• Potential shift towards biosimilar adoption, lowering treatment costs.

Legal and Patent Outlook

• Patent expiry in 2023 opens the market to biosimilar entrants.
• Litigation and patent defenses remain active, impacting market entry timelines.

Market Opportunities and Risks

Opportunities

• Expansion into emerging markets with increasing healthcare infrastructure.
• Development of novel formulations with enhanced stability and bioavailability.
• New indications for malnutrition, inflammatory bowel disease, or other gastrointestinal disorders.

Risks

• Market saturation among existing products.
• Regulatory delays for biosimilars or new formulations.
• Reimbursement challenges, especially in cost-sensitive markets.
• Supply chain vulnerabilities impacting production of porcine enzymes.

Key Takeaways

• Pancreaze is a mature product with stable revenues but faces imminent patent expiry.
• Competition from biosimilars and generics is expected to pressure prices.
• Growth depends on innovation in formulations and expanding indications.
• Geographic expansion into emerging markets could offset mature-market declines.
• Regulatory and supply chain risks remain significant, influencing future financial stability.

FAQs

1. How will patent expiry impact Pancreaze’s market share?
Patent expiry allows biosimilar competitors to enter in 2023, increasing price competition and potentially reducing Pancreaze revenues by 10%-15% annually unless new formulations or pipeline products are successfully launched.

2. What drives growth in the PEI market?
Rising cystic fibrosis prevalence, increased diagnosis of pancreatic conditions, and off-label use for malnutrition contribute to ongoing growth. Technological improvements and broader awareness further support market expansion.

3. Are biosimilars likely to replace Pancreaze?
Yes, biosimilars are expected to enter the market post-patent expiry, offering lower-cost alternatives. However, regulatory approval processes and market acceptance influence their adoption pace.

4. What are the main challenges facing Pancreaze’s financial stability?
Patent expiration, competition, pricing pressures, regulatory hurdles for biosimilar entry, and supply chain disruptions for pig-derived enzymes threaten revenue stability.

5. How is AbbVie positioning itself in this evolving market?
AbbVie invests in reformulation R&D, explores new indications, and pursues geographic expansion. It also defends patent rights and competes on clinical data quality and pricing strategies.

---

Sources
[1] Grand View Research. (2022). Pancreatic Enzyme Replacement Therapy Market Size, Share & Trends.
[2] U.S. Food and Drug Administration. (2009). Approval of Pancreaze.
[3] MarketWatch. (2023). Biologics Market Overview and Future Trends.